Inactive Instrument

Highlights Spring Bank Pharmaceuticals, Inc.

Equities

SBPH

US8494311017

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

F-Star Therapeutics Limited completed the acquisition of Spring Bank Pharmaceuticals, Inc. in a reverse merger transaction.	20-11-19	CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-03	CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-10	CI
F-Star Therapeutics Limited entered into a definitive agreement to acquire Spring Bank Pharmaceuticals, Inc. for $90.6 million in a reverse merger transaction.	20-07-28	CI
Spring Bank Pharmaceuticals, Inc. Advances IV SB 11285 Clinical Program	20-06-03	CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-07	CI
Spring Bank Pharmaceuticals, Inc. Announces New Clinical Collaboration with Roche	20-02-25	CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-14	CI
Spring Bank Pharmaceuticals, Inc. Discontinues Development of Inarigivir for the Treatment of HBV	20-01-29	CI
Spring Bank Pharmaceuticals, Inc Announces Update on Phase 2B Catalyst Trials	19-12-26	CI
Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285	19-11-20	CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-07	CI
Spring Bank Pharmaceuticals, Inc. Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B Patients	19-10-17	CI
Yale Cancer Center to Present on the Synergistic Relationship Between Intravenously-Administered SB 11285, Spring Bank’S Sting Agonist Development Compound, and Radiation Therapy in Cancer at the 2019 ASTRO Annual Meeting	19-09-17	CI
Spring Bank Pharmaceuticals, Inc. Enters into Research Agreement with the University of Texas Southwestern Medical School	19-08-06	CI
Spring Bank Announces Collaborative Research Agreement with University of Texas Southwestern Medical School for Evaluation of STING Antagonist Compounds	19-08-06	CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-07-31	CI
Spring Bank Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for SB 11285	19-07-29	CI
Spring Bank Announces Dosing of Inarigivir 400Mg in Multiple HBV Studies	19-07-23	CI
Spring Bank Announces Research Agreement with the National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide Compounds	19-07-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Spring Bank Pharmaceuticals, Inc.

Equities

SBPH

US8494311017

Highlights

Filters